Latest market price
138.64
-2.03-1.44%
TFXQT61Teleflex Incorporated·NYSE
138.64-1.44%
TA
Loading chart...
Screen all →
Snapshot
Index—P/E—EPS (ttm)-23.29Insider Own0.94%Shs Outstand42.37MPerf Week2.83%
Market Cap5.96BForward P/E12.85EPS next Y10.95Insider Trans0.00%Shs Float42.21MPerf Month13.33%
Enterprise Value8.53BPEG—EPS next Q1.90Short Float9.99%Perf Quarter0.39%
Income-1.03BP/S2.29EPS this Y-48.51%Short Ratio6.18Perf Half Y17.33%
Sales2.60BP/B2.05EPS next Y51.70%ROA-15.17%Short Interest4.22MPerf YTD15.27%
Book/sh68.56P/C19.87EPS next 5Y18.51%ROE-31.83%52W High145.00 -4.39%Perf Year12.68%
Cash/sh7.08P/FCF15.21EPS past 3/5Y—ROIC1.30%52W Low100.18 38.39%Perf 3Y-22.26%
Dividend Est.1.36 (0.98%)EV/EBITDA—Sales past 3/5Y-10.62% -4.71%Gross Margin53.77%Volatility2.51% 2.67%Perf 5Y-62.68%
Dividend TTM1.36 (0.98%)EV/Sales3.28EPS Y/Y TTM-648.00%Oper. Margin3.35%ATR (14)3.71Perf 10Y-16.17%
Dividend Ex-DateAug 14, 2026Quick Ratio2.12Sales Y/Y TTM-14.50%Profit Margin-39.58%RSI (14)69.24Recom2.45
Dividend Gr. 3/5Y0.00% 0.00%Current Ratio2.60EPS Q/Q-52.82%SMA206.92%Beta0.81Target Price154.25
Payout—Debt/Eq0.99Sales Q/Q-27.02%SMA507.08%Rel Volume1.27Prev Close140.67
Employees15,500LT Debt/Eq0.96EarningsNov 05SMA20012.23%Avg Volume725.18KPrice138.64
IPO DateMar 17, 1980Option/ShortYes / YesEPS/Sales Surpr.37.36% 1.91%Net Debt/EBITDA—Volume923,082Change-1.44%
Analyst Ratings
DateActionAnalystRatingTarget
Oct-14-26ReiteratedTruist SecuritiesHold$150 → $142
Sep-28-26UpgradeB of A SecuritiesNeutral → Buy
Aug-25-26ReiteratedNeedhamBuy$159 → $170
Aug-11-26ReiteratedUBSNeutral$145 → $158
Aug-10-26ReiteratedTruist SecuritiesHold$135 → $150
Jul-31-26ReiteratedNeedhamBuy$147 → $159
Jul-28-26InitiatedUBSNeutral$145
Jul-08-26InitiatedBMO CapitalOutperform$159
Jun-08-26UpgradePiper SandlerNeutral → Overweight$245 → $160
May-08-26ReiteratedRaymond JamesOutperform$128 → $150
Latest News· Times ET
Oct-27-26
Oct-22-26
Oct-15-26
Oct-12-26
Oct-08-26
Oct-06-26
Oct-02-26
Sep-29-26
Sep-28-26
Sep-20-26
Sep-16-26
Company

Teleflex Incorporated is a global medical technology company dedicated to designing, developing, manufacturing, and distributing single-use medical devices. These products are crucial for diagnostic and therapeutic procedures, particularly within critical care and surgical environments worldwide. Its comprehensive product portfolio includes: Vascular Access Solutions: Featuring the "Arrow" brand, these include catheters, advanced catheter navigation and tip positioning systems, and intraosseous access systems. They are essential for administering intravenous therapies, monitoring blood pressure, and drawing blood samples, all achievable through a single access point. Interventional Cardiology & Radiology Products: This segment covers various coronary catheters, therapies for structural heart conditions, and devices for peripheral intervention and cardiac assist. Key users include interventional cardiologists, radiologists, and vascular surgeons. Specific offerings comprise Arrow, Guideline, and Trapliner catheters, the Manta Vascular Closure Device, and Arrow Oncontrol systems. Anesthesia and Surgical Products: The company provides anesthesia and pain management products, serving hospitals, emergency medical services, and military health organizations. Its surgical division offers metal and polymer ligation clips, fascial closure systems for laparoscopic procedures, percutaneous surgical systems, and a range of other surgical instruments. Interventional Urology & General Urology: Teleflex's interventional urology offerings prominently feature the UroLift System, an innovative treatment for lower urinary tract symptoms associated with benign prostatic hyperplasia (BPH). Additionally, it supplies general urology products like catheters, urine collection devices, catheterization accessories, and tools for operative endourology, alongside providing bladder management services. Respiratory Care Products: This category includes oxygen and aerosol therapy devices, spirometry equipment, and ventilation management systems, applicable across diverse healthcare settings. Teleflex serves a broad customer base, encompassing hospitals, healthcare providers, medical device manufacturers, and the home care market. Established in 1943, the company maintains its headquarters in Wayne, Pennsylvania.

Ownership

Per-holder 13F data hasn't been ingested for this ticker yet.

Financial Statements
DataTimeframe
Line Item (USD, M)
TTM
—
FY 2025
12/31/2025
FY 2024
12/31/2024
FY 2023
12/31/2023
FY 2022
12/31/2022
FY 2021
12/31/2021
FY 2020
12/31/2020
FY 2019
12/31/2019
FY 2018
12/31/2018
Total Revenue2,6001,9933,0472,974—————
Cost of Goods Sold Incl. D&A1,2038721,3451,328—————
Gross Profit1,3981,1211,7031,647—————
Selling, General and Administrative Excl. Other944720995930—————
Research and Development195145162154—————
Other Operating Expense171039557—————
Operating Income86256151506—————
Interest Expense1201008485—————
Unusual Expense
—————————
Non-Operating Income (Expense)-377-131813—————
Net Income Before Taxes-4102575434—————
Income Taxes-35-34576—————
Consolidated Net Income-1,029-90670356—————
Net Income From Continuing Operations-3765970358—————
Net Income-1,029-90670356—————
EPS (Recurring)-23.28-20.301.497.58—————
EPS (Basic, Before Extraordinaries)-23.28-20.301.497.58—————
EPS (Diluted)-23.29-20.251.487.53—————
EBITDA-158303434761—————
Other After Tax Adjustments
—————————
Stock Option Compensation Expense
—————————
Price To Earnings Ratio——120.2633.11—————
Price To Sales Ratio2.352.762.753.94—————
Gross Margin53.7756.2555.8955.38—————
Operating Margin3.3112.844.9617.01—————
Net Margin-39.58-45.462.3011.97—————
Shares Outstanding44454747—————
Market Capitalization6,1005,4928,36511,719—————
Operating Lease Expense
—————————
Unlock full historical data
See years of past statements with Premium.
Unlock with Premium
Insider Trading Volume
$148.31$134.75$121.19$107.64$94.08● Close Price0.00K0.00K0.00K0.00K0.00KUSD Trades VolumeNovDec2026FebMarAprMayJunJulAugSepOctNov
Insider Trading
InsiderRelationshipDateTransactionCost#SharesValue ($)#Shares TotalSEC Form 4
HAGGERTY GRETCHEN RDirectorAug 06 '25Buy114.7550057,3756,305Aug 07
Ryu JaewonDirectorAug 05 '25Buy115.001,500172,5003,727Aug 07
Kelly LiamChairman, President & CEOAug 05 '25Buy115.071,500172,60545,267Aug 07
Krakauer Andrew ADirectorAug 05 '25Buy115.251,000115,2507,192Aug 07
RANDLE STUART ADirectorAug 05 '25Buy115.861,000115,8607,547Aug 07
Duncan Candace HDirectorMay 05 '25Option Exercise123.044,833594,6529,561May 07
Klasko Stephen K. M.D.DirectorFeb 20 '25Option Exercise121.002,674323,5549,827Feb 21
Logue Daniel V.CVP, General Counsel & SectyFeb 20 '25Option Exercise121.001,620196,02014,328Feb 21
Kelly LiamChairman, President & CEOFeb 19 '25Option Exercise121.4136,4644,427,19963,556Feb 21
RANDLE STUART ADirectorAug 16 '24Sale238.932,674638,8995,496Aug 16
RANDLE STUART ADirectorAug 16 '24Option Exercise121.002,674323,5548,170Aug 16
Hicks Cameron PCorp. VP & Chief HR OfficerMar 05 '24Sale225.007,4011,665,22510,050Mar 05
Hicks Cameron PCorp. VP & Chief HR OfficerMar 05 '24Option Exercise135.147,4011,000,19717,451Mar 05
Logue Daniel V.CVP, General Counsel & SectyFeb 26 '24Option Exercise101.121,525154,20812,278Feb 28
Kelly LiamChairman, President & CEODec 27 '23Option Exercise101.8726,2562,674,57144,726Dec 29
QuoTrend signals describe historical patterns and statistics — educational information, not investment advice or a recommendation to buy or sell. Past performance doesn’t guarantee future results. Every figure traces to QuoTrend data. Historical patterns — not a prediction or advice.